A Phase II Study Evaluating the Efficacy and Safety of XH-S003 Capsules in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) (XH-S003-II-101)

S-INFINITY Pharmaceuticals Co., Ltd

Status and phase: Enrolling; Phase 2

Conditions: PNH - Paroxysmal Nocturnal Hemoglobinuria

Treatments: Drug: XH-S003 Capsule

Study type: Interventional

Funder types: Industry

Identifiers

NCT06978699

XH-S003-II-101

Details and patient eligibility

About

This is a multicenter, randomized, single-blind Phase II trial to evaluate the efficacy and safety of XH-S003 capsules in PNH patients. About 24 PNH patients will be enrolled and randomized to three dose levels and take XH-S003 capsules orally

Enrollment: 24 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female with aged ≥18 years old;
• Weight ≥40 kg and BMI≥18 kg/m2 ;
• Diagnosed with PNH: with red blood cell or granulocyte clone levels >10% detected by flow cytopy within 6 months prior to screening or during screening;
• Patients who have not previously received any complement inhibitor therayp;
• LDH > 1.5×ULN detected two times during the screening period (interval of 2 to 8 weeks);
• Hb meets one of the following conditions: (1) Hb <100 g/L at the first screening visit, and subjects receive RBC transfusion because of PNH-related anemia during the screening period; (2) The average Hb of two tests during the screening period <100 g/L (interval of 2~8 weeks);
• Vaccination against Neisseria meningitidis and Streptococcus pneumoniae before the first administration. If the subject has not been vaccinated previously or requires booster vaccination (according to local vaccination policies), vaccination must be administered at least 2 weeks before the first administration. If the first administration must begin less than 2 weeks after vaccination, preventive antibiotic treatment must begin at least 2 weeks after vaccination;

Exclusion criteria

• Subjects with laboratory evidence of bone marrow failure during the screening period (reticulocyte count <100×109/L, platelet count <30×109/L, or neutrophil count <0.5×109/L);

• Subjects receiving other therapies prior to screening who have not achieved the following treatment durations:

  • Erythropoietin or immunosuppressants for at least 8 weeks; • Systemic corticosteroids for at least 4 weeks; • Iron supplements, vitamin B12, or folic acid for at least 4 weeks; • Anticoagulants: Vitamin K antagonists for at least 4 weeks with stable international normalized ratio (INR) (as determined by the investigator), low molecular weight heparin for at least 4 weeks; • Hypoxic-inducing factor prolyl hydroxylase inhibitors (HIF-PHI) for at least 8 weeks; • Androgens for at least 4 weeks;

• A history of bone marrow/hematopoietic stem cell or solid organ transplantation;

• Alanine aminotransferase (ALT), γ-glutamyl transpeptidase (GGT), or alkaline phosphatase (ALP) >3×ULN at screening; - Positive HIV antibody, active syphilis infection, positive HBsAg, active HCV infection, or active tuberculosis infection at screening;

• Known or suspected immunodeficiency diseases or hereditary complement deficiency at screening;

• A history of Neisseria meningitidis infection;

• Subjects with chronic active or recurrent infections within 1 year prior to screening;

• Subjects with systemic active bacterial, viral (including COVID-19), or fungal infections within 2 weeks prior to the first administration; subjects with body temperature >38°C within 7 days prior to the first administration;

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

24 participants in 3 patient groups

Dose 1

Experimental group

Description:

Once daily

Treatment:

Drug: XH-S003 Capsule

Dose 2

Experimental group

Description:

Once daily

Treatment:

Drug: XH-S003 Capsule

Dose 3

Experimental group

Description:

Once daily

Treatment:

Drug: XH-S003 Capsule